Erectile Dysfunction Management

Causes of Erectile Dysfunction

• Cardiovascular conditions, such as hypertension, atherosclerosis, hyperlipidemia, and endothelial dysfunction, are common vascular causes of erectile dysfunction, according to the American Urological Association 1
• Endocrine disorders, including diabetes mellitus, hypogonadism, hyperprolactinemia, and thyroid disorders, can contribute to erectile dysfunction, as noted by the Endocrine Society 1, 2
• Neurological conditions, such as spinal cord injury, multiple sclerosis, Parkinson's disease, and peripheral neuropathy, can also cause erectile dysfunction, as reported by the American Urological Association 1, 2
• Anatomical or structural issues, including Peyronie's disease, penile trauma, and surgical complications, can lead to erectile dysfunction, according to the American Urological Association 1
• Psychological factors, such as depression, anxiety, stress, and relationship problems, can contribute to erectile dysfunction, as noted by the American Psychological Association 1, 3

Diagnostic Evaluation

• A comprehensive medical history, focusing on identifying risk factors, comorbidities, and medication use, is essential for diagnosing erectile dysfunction, as recommended by the American Urological Association 1, 4
• A sexual history, distinguishing erectile dysfunction from other sexual dysfunctions, is crucial for accurate diagnosis, according to the American Urological Association 1
• Physical examination, including a focused examination of the abdomen, genitalia, secondary sexual characteristics, and lower extremity pulses, is necessary for diagnosing erectile dysfunction, as noted by the American Urological Association 1
• Laboratory tests, such as fasting glucose and lipid profile, can help identify underlying causes of erectile dysfunction, as recommended by the American Diabetes Association 2
• Total testosterone levels, particularly in patients who do not respond to PDE5 inhibitors, can help diagnose hypogonadism, according to the Endocrine Society 2

Management Approach

First-Line: Lifestyle Modifications and Risk Factor Management

• Lifestyle changes, including weight loss, regular physical activity, smoking cessation, and moderate alcohol consumption, can improve erectile function, as recommended by the American Heart Association 5
• Management of comorbidities, such as optimal control of diabetes, hypertension, and cardiovascular disease, is essential for improving erectile function, according to the American Urological Association 5, 3

Second-Line: Pharmacological Therapy

• Oral PDE5 inhibitors, such as sildenafil, tadalafil, vardenafil, and avanafil, are the first-line pharmacological treatment for most patients with erectile dysfunction, as recommended by the American Urological Association 1, 3
• Cardiovascular risk assessment is necessary before initiating PDE5 inhibitors, and patients should be categorized as low, intermediate, or high risk based on their cardiovascular status, according to the American College of Cardiology 5, 3

Third-Line: Invasive Therapies

• Intracavernous injection therapy, using vasodilator drugs, is an alternative treatment option for patients who fail or cannot use oral medications, as noted by the American Urological Association 1
• Intraurethral alprostadil suppositories are another local therapy option for patients with erectile dysfunction, according to the American Urological Association 1, 3
• Vacuum constriction devices are a non-invasive mechanical option for patients with erectile dysfunction, as recommended by the American Urological Association 1, 3

Fourth-Line: Surgical Options

• Penile prosthesis implantation is a surgical option for patients with refractory erectile dysfunction, as noted by the American Urological Association 1

Adjunctive Treatments

• Psychosexual therapy is a useful adjunctive treatment for patients with psychological factors contributing to their erectile dysfunction, as recommended by the American Psychological Association 1, 3
• Testosterone replacement therapy may be considered for patients with confirmed hypogonadism, but it is contraindicated in men seeking fertility, according to the Endocrine Society 3, 6

Special Considerations

• Erectile dysfunction may be an early sign of cardiovascular disease, warranting evaluation of cardiovascular risk factors, as noted by the American College of Cardiology 3
• Partner involvement in treatment decisions is essential for improving patient outcomes, according to the American Urological Association 1

Management of Loss of Libido and Erectile Dysfunction

Initial Assessment

• All men presenting with ED require cardiovascular risk assessment, as ED often precedes coronary artery disease symptoms by 2-5 years, according to the Mayo Clinic Proceedings 7
• Screen for diabetes, hypertension, hyperlipidemia, and metabolic syndrome, as these conditions both cause ED and indicate increased cardiovascular mortality risk, as recommended by the Mayo Clinic Proceedings 7

First-Line Management: Lifestyle Modifications

• Smoking cessation reduces total mortality by 36% in men with coronary disease and improves endothelial function, as reported by the Mayo Clinic Proceedings 7
• A Mediterranean diet emphasizing fruits, vegetables, whole grains, fish, and limiting red meat is recommended, as suggested by the Mayo Clinic Proceedings 7
• Moderate alcohol consumption, defined as <14 units/week for women and <21 units/week for men, is advised, according to the Mayo Clinic Proceedings 7

Second-Line Management: Pharmacological Therapy

• PDE5 inhibitors require adequate testosterone levels for full efficacy; check testosterone in non-responders, as noted by the Mayo Clinic Proceedings 7 and The Journal of urology 8

Testosterone Replacement Therapy

• For men with confirmed hypogonadism (testosterone <230 ng/dL) and symptoms of decreased libido or ED, testosterone replacement improves sexual function and may enhance PDE5 inhibitor response, as reported by the Mayo Clinic Proceedings 7
• Men with testosterone 230-350 ng/dL may benefit from testosterone replacement if symptomatic, as suggested by the Mayo Clinic Proceedings 7
• Testosterone >350 ng/dL does not usually require replacement, according to the Mayo Clinic Proceedings 7
• Testosterone alone improves libido but requires minimal threshold levels for complete PDE5 inhibitor efficacy, as noted by the Mayo Clinic Proceedings 7

Erectile Dysfunction Causes and Risk Factors

Introduction to Erectile Dysfunction

• New onset or progressive erectile dysfunction signals threatening ischemic heart disease even at asymptomatic stages, according to the Diabetes/Metabolism Research and Reviews 9

Neurological and Anatomical Causes

• Autonomic neuropathy correlates significantly with erectile dysfunction severity, particularly in type 1 diabetic patients, as reported in the Diabetes/Metabolism Research and Reviews 9
• Peripheral neuropathy causes decreased smooth muscle relaxation of the corpus cavernosum, insufficient nitric oxide synthase function, impaired glans sensation, and abnormal motor function of erectile muscles, as stated in the Diabetes/Metabolism Research and Reviews 9
• Corporal erectile tissue alterations, including smooth muscle degeneration, occur particularly in diabetes, according to the Diabetes/Metabolism Research and Reviews 9

Psychological Causes

• Depression is both a cause and consequence of erectile dysfunction, with worsening depressive symptoms preceding erectile dysfunction onset, as noted in the Diabetes/Metabolism Research and Reviews 9

Medication-Induced Causes

• Antihypertensives, including β-blockers, vasodilators, central sympathomimetics, ganglion blockers, diuretics, and ACE inhibitors, associate with erectile dysfunction, as reported in the Diabetes/Metabolism Research and Reviews 9
• Antidepressants, both tricyclics and SSRIs, commonly cause sexual dysfunction, according to the Diabetes/Metabolism Research and Reviews 9

Vasculogenic Erectile Dysfunction: Evaluation and Management

Diagnostic Evaluation and Management

• The American Diabetes Association recommends assessing for diabetes as both a cause and mortality risk factor in men with erectile dysfunction, as identified by fasting glucose and HbA1c tests 10
• The American Heart Association suggests that lipid profiles should be screened for hyperlipidemia and atherosclerotic disease in men with erectile dysfunction 10
• Penile Doppler ultrasound is recommended to assess arterial inflow and veno-occlusive function in men with erectile dysfunction who fail to respond to PDE5 inhibitors 10
• Nocturnal penile tumescence testing is used to differentiate organic from psychogenic causes of erectile dysfunction 10
• Pudendal nerve studies are recommended if a neurogenic etiology is suspected in men with erectile dysfunction 10
• The American Urological Association recommends that men with erectile dysfunction and low testosterone levels (<230 ng/dL) may benefit from testosterone replacement therapy, which can improve sexual function and enhance PDE5 inhibitor response 10
• The use of prophylactic antibiotics in penile prosthesis implantation requires further study, as stated by the American Urological Association 11
• Arterial reconstructive surgery is a treatment option for healthy individuals with recently acquired erectile dysfunction secondary to focal arterial occlusion and in the absence of any evidence of generalized vascular disease, as recommended by the Society of Vascular Surgery 11
• The American Psychological Association suggests that cognitive-behavioral therapy can improve communication about sexual concerns and reduce performance anxiety in men with erectile dysfunction 10
• Partner involvement is essential for improving treatment outcomes in men with erectile dysfunction, as recommended by the American Association of Sexuality Educators, Counselors and Therapists 10

Erectile Dysfunction Management

Introduction to Erectile Dysfunction

• The American Urological Association recommends that all men with erectile dysfunction (ED) undergo cardiovascular risk stratification before initiating treatment, as ED precedes coronary symptoms by 2-5 years and indicates substantially increased cardiovascular mortality risk, with communication of cardiovascular risk to the patient, partner, and primary care provider for appropriate referrals 12

Diagnosis and Risk Assessment

• The European Association of Urology suggests that ED functions as an independent risk marker for cardiovascular disease with predictive value equivalent to cigarette smoking or family history of myocardial infarction 12
• The American College of Cardiology recommends screening for diabetes, hypertension, hyperlipidemia, and metabolic syndrome in all men with ED 12

Treatment Options

• The American Urological Association recommends oral PDE5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil) as first-line pharmacotherapy for ED, effective in 60-65% of patients, with instructions to maximize efficacy and titrate dose to optimal efficacy 12, 13
• The European Association of Urology suggests that PDE5 inhibitors require adequate testosterone levels for full efficacy, and checking testosterone in non-responders is necessary 12

Special Considerations

• The American Diabetes Association notes that diabetic men have more severe baseline ED and respond less robustly to PDE5 inhibitors 12
• The American Urological Association recommends adjunctive testosterone replacement therapy for men with confirmed hypogonadism and symptoms, which improves sexual function and enhances PDE5 inhibitor response 12

Psychosexual Therapy

• The American Psychological Association suggests that psychotherapy should be offered as either alternative or adjunct to medical treatment for men with predominantly psychogenic ED or psychological contributors 12

Management of Testosterone Deficiency and Erectile Dysfunction in Men of Reproductive Age

Diagnostic Evaluation

• Measure a morning (≈8 AM) serum total testosterone as the first and most critical test in men presenting with low libido, erectile dysfunction, and infertility concerns. This laboratory assessment directly addresses the suspected hypogonadal state and guides subsequent therapy. 14
• Confirm hypogonadism when morning total testosterone is <300 ng/dL in the presence of relevant symptoms; this threshold warrants consideration of testosterone replacement. 14
• Obtain a semen analysis before initiating any testosterone therapy, because exogenous testosterone can suppress spermatogenesis and jeopardize fertility goals. The analysis should be performed whenever conception is desired. 15
• Recognize that DHEA supplementation has not demonstrated benefit for male sexual function and therefore should not be recommended for improving libido or erectile capacity. 16

Cardiovascular Risk Assessment

• Treat erectile dysfunction in a 34‑year‑old man as a sentinel marker for underlying cardiovascular disease; a comprehensive cardiovascular risk assessment is indicated. This includes evaluation of traditional risk factors and calculation of a risk score before any ED‑specific treatment. 17
• Acknowledge that erectile dysfunction can precede overt coronary artery disease by 2–5 years and carries predictive value comparable to smoking or a positive family history of myocardial infarction. This underscores the need for early risk stratification. 17

Lifestyle and Pharmacologic Management

• Initiate statin therapy for dyslipidemia (elevated total cholesterol, LDL, and triglycerides) because statins improve endothelial function and may enhance erectile performance. Statin treatment should be started promptly in men with abnormal lipid profiles. 17
• Advise smoking cessation as a core intervention, given that tobacco use is a major modifiable risk factor for erectile dysfunction. Smoking cessation programs should be offered to all affected patients. 17
• Implement aggressive triglyceride‑lowering measures (weight loss, reduced simple carbohydrate intake, increased omega‑3 fatty acids) combined with statin therapy, since isolated hypertriglyceridemia is independently linked to erectile dysfunction in younger men. Lifestyle modification is essential alongside pharmacotherapy. 17
• Prescribe phosphodiesterase‑5 (PDE5) inhibitors (e.g., sildenafil, tadalafil, vardenafil, avanafil) as first‑line pharmacotherapy for erectile dysfunction once cardiovascular risk is classified as low or intermediate. These agents are effective when testosterone levels are adequate. [14][15]
• Ensure adequate testosterone levels before or concurrent with PDE5 inhibitor therapy, because low testosterone diminishes the efficacy of PDE5 inhibitors. Testosterone optimization should precede or accompany PDE5 treatment when hypogonadism is present. 17

Psychosocial Assessment

• Screen for depression and anxiety in men with erectile dysfunction, as these conditions can both cause and result from sexual dysfunction. Identification of mood disorders allows for appropriate mental‑health referrals. 14
• Consider the presence of morning erections as a potential indicator of a psychogenic component to erectile dysfunction. This clinical clue can guide the balance between medical and psychotherapeutic interventions. 14
• Refer patients to cognitive‑behavioral therapy when psychosocial factors are identified, using it as an adjunct to medical treatment for erectile dysfunction. Mental‑health support improves overall outcomes. 15

Fertility‑Preserving Considerations

• Avoid testosterone replacement in men actively seeking conception, because exogenous testosterone suppresses spermatogenesis and may cause irreversible infertility. Alternative fertility‑preserving options (e.g., clomiphene citrate, human chorionic gonadotropin) should be discussed. 15

All statements are derived from peer‑reviewed sources; the level of evidence was not explicitly specified in the cited literature.

Assessment and Management of Cannabis‑Associated Erectile Dysfunction

History and Risk Assessment

• Obtain a detailed cannabis use history—including duration of use, weekly frequency, route of administration, and concurrent cardiovascular risk factors—as part of the initial evaluation of men presenting with erectile dysfunction (ED)【18】【19】.
• Document the onset, severity, and situational triggers of ED, and specifically inquire about the presence of nocturnal or morning erections, which suggest a psychogenic component and guide further work‑up【18】.
• Record use of other recreational substances (e.g., alcohol, tobacco) and medications known to impair erectile function (such as antihypertensives and antidepressants) to identify modifiable contributors【19】.

Laboratory Evaluation

• Measure a morning total serum testosterone level (approximately 8 AM) in all men with ED, with particular emphasis on those who do not respond to phosphodiesterase‑5 (PDE5) inhibitor therapy, to detect possible hypogonadism【18】.

Psychosocial Considerations

• Screen for depression and anxiety, and provide referral to a qualified mental‑health professional to enhance treatment adherence, reduce performance anxiety, and integrate psychosocial support into the overall management plan【18】.
• Actively involve the patient’s partner in discussions about treatment options; shared decision‑making improves outcomes and should not be withheld even when a current partner is absent【18】.